Radiotherapy, a clinically used local treatment modality of cancers, is regarded as a promising candidate to promote current immunotherapy through initiating an in situ vaccination effect and reprogramming the immunosuppressive microenvironment. The combination of radiotherapy and immunotherapy, referred to as combinational radio–immuno oncotherapy (CRIOT), elicits a synergistic antitumor effect based on the immunomodulatory properties of radiation. Unfortunately, current CRIOT accompanies low response rate and severe toxicity in clinical trials, thus limiting its application. To this end, various nanomaterials are being developed to sensitize radiotherapy or deliver immune agents, or both, to improve the unsatisfactory outcomes of CRIOT. Herein, enhanced antitumor efficacy of CRIOT with nanomaterials through the possible mechanisms of rejuvenation and activation of T cells, increased presentation of tumor‐related antigens, and inhibition of suppressive macrophages is presented, and the prospect of CRIOT in clinical practice is proposed.
Irradiation of the selective regional lymph node and the correlated lymphatic drainage regions should be performed according to the clinicopathological factors. For the large, deeply invasive longer tumors and poorly differentiated thoracic ESCC, the irradiation field should be enlarged appropriately.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.